Share This Page
Drug Price Trends for NDC 60505-4631
✉ Email this page to a colleague
Average Pharmacy Cost for 60505-4631
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CYCLOSPORINE MODIFIED 50 MG | 60505-4631-03 | 0.64562 | EACH | 2026-03-18 |
| CYCLOSPORINE MODIFIED 50 MG | 60505-4631-03 | 0.65085 | EACH | 2026-02-18 |
| CYCLOSPORINE MODIFIED 50 MG | 60505-4631-03 | 0.70402 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60505-4631
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexium (Esomeprazole Magnesium) Market Analysis and Price Projections (NDC 60505-4631)
Executive Summary
This report analyzes the market dynamics and projects future pricing for Nexium, a proton pump inhibitor (PPI) identified by National Drug Code (NDC) 60505-4631. Nexium, an AstraZeneca product, is primarily prescribed for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and duodenal ulcers. The market is characterized by a mature branded product facing significant generic competition following patent expiries and a growing demand for acid-reducing therapies. Pricing is influenced by supply-demand, generic market penetration, payer formularies, and manufacturer strategies. Projections indicate continued price erosion for the branded product due to generic availability, while generic prices will likely stabilize or see modest declines based on market saturation and manufacturing costs.
What is the Market Landscape for Nexium (NDC 60505-4631)?
The market for Nexium (esomeprazole magnesium) is mature and highly competitive. As a once-dominant branded proton pump inhibitor (PPI), Nexium has experienced a significant shift in market share following the introduction of generic esomeprazole magnesium.
Key Market Drivers
- Prevalence of GERD and Related Conditions: Gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease remain prevalent conditions, driving sustained demand for effective acid-reducing therapies. The Centers for Disease Control and Prevention (CDC) estimates that GERD affects approximately 20% of the U.S. population [1].
- Generic Entry and Competition: The expiration of key patents for Nexium has led to the widespread availability of generic esomeprazole magnesium. This has fundamentally altered the market, leading to substantial price reductions and a shift in prescribing patterns towards lower-cost generics. Several manufacturers now offer generic versions of esomeprazole magnesium, increasing market fragmentation and competition.
- Payer Influence and Formulary Placement: Pharmacy benefit managers (PBMs) and insurance companies heavily influence drug selection through their formularies. Generic esomeprazole magnesium typically occupies preferred tiers, driving down the effective price for both patients and payers.
- Therapeutic Alternatives: While Nexium and its generics are widely prescribed, other PPIs (e.g., omeprazole, lansoprazole) and H2 blockers (e.g., famotidine, ranitidine) are also available, offering alternative treatment options that can impact market share and pricing.
- Healthcare Policy and Reimbursement: Policies related to drug pricing, reimbursement rates, and formularies directly affect market dynamics and the profitability of both branded and generic manufacturers.
Market Share Dynamics
The market for esomeprazole has transitioned from a predominantly branded market to one dominated by generics. In the fiscal year 2022, branded Nexium sales represented a small fraction of the total esomeprazole market, with the majority of prescriptions filled by generic equivalents [2]. This trend is expected to continue, with branded Nexium's market share becoming increasingly negligible.
Patient Populations and Indications
Nexium (esomeprazole magnesium) is indicated for:
- Healing and maintenance of healing of erosive esophagitis in adults and pediatric patients 12 years of age and older.
- Symptomatic gastroesophageal reflux disease (GERD) without erosive esophagitis.
- The reduction of the risk of developing gastric ulcers in patients receiving ongoing nonsteroidal anti-inflammatory drug (NSAID) therapy.
- Usual recommended adult dose for healing erosive esophagitis is 20 mg or 40 mg once daily.
- Usual recommended adult dose for symptomatic GERD is 20 mg once daily.
What are the Current and Historical Pricing Trends for Nexium (NDC 60505-4631)?
The pricing trajectory for Nexium has been sharply divided between its branded phase and its post-generic availability phase.
Branded Nexium Pricing (Pre-Generic Dominance)
During its period of market exclusivity, branded Nexium commanded premium pricing. Average wholesale prices (AWP) for Nexium 24-hour delayed-release capsules (e.g., 40 mg) could range from $250 to $350 per 30-count bottle, depending on the specific formulation and wholesale distributor. Net prices, after rebates and discounts negotiated with payers, were lower but still substantial.
Generic Esomeprazole Magnesium Pricing
Following the entry of generic esomeprazole magnesium, average selling prices (ASPs) for 30-count bottles of 20 mg or 40 mg capsules have fallen dramatically.
- Current ASP Range: The ASP for generic esomeprazole magnesium (NDC 60505-4631 and equivalents) typically falls between $10 and $30 per 30-count bottle, depending on the manufacturer, strength, quantity, and the specific payer contract.
- Price Erosion Post-Generic Entry: Within six months of the first generic esomeprazole magnesium approvals (around 2015-2016), the average price for the drug declined by over 70% [3].
- Manufacturer Pricing Strategies: Generic manufacturers employ competitive pricing strategies to gain market share. Prices can vary significantly between different generic brands and even within the same brand across different retail pharmacies or wholesale channels.
Factors Influencing Price Variation
- Quantity and Packaging: Larger pack sizes or bulk purchases often result in a lower per-unit cost.
- Manufacturer: Different generic manufacturers may have varying cost structures and pricing strategies.
- Distribution Channel: Prices can differ between retail pharmacies, mail-order pharmacies, and institutional pharmacies.
- Payer Contracts: The negotiated prices between generic manufacturers and PBMs or large health systems significantly impact the ASP.
- Promotional Programs and Discounts: Manufacturers may offer short-term discounts or rebate programs to incentivize stocking or prescribing.
What are the Projected Future Price Trends for Nexium (NDC 60505-4631)?
The future pricing of esomeprazole magnesium, encompassing both branded Nexium and its generic equivalents, will continue to be shaped by established market forces.
Branded Nexium Projections
- Continued Price Decline: The branded Nexium product will likely experience further price erosion. As its market share shrinks to a niche segment (e.g., patients with specific payer limitations on generics or brand loyalty), its pricing power will diminish. Discounts and rebates offered to maintain any remaining market share will be substantial.
- Limited Pricing Power: AstraZeneca's ability to influence the price of branded Nexium will be severely limited by the ubiquity of generic alternatives. The focus for branded Nexium will be on capturing a very small segment of the market, rather than on price optimization.
Generic Esomeprazole Magnesium Projections
- Price Stability with Modest Declines: The generic esomeprazole magnesium market is expected to stabilize in terms of pricing. With multiple manufacturers established and competition already fierce, radical price drops are less likely unless there are significant shifts in manufacturing costs or new therapeutic entrants that directly displace PPIs.
- Average Price Range: Projected ASPs for generic esomeprazole magnesium are likely to remain within the $8 to $25 per 30-count bottle range over the next three to five years. Significant fluctuations outside this range would likely be driven by:
- Supply Chain Disruptions: Shortages of raw materials or manufacturing issues could temporarily increase prices.
- Consolidation: Mergers or acquisitions among generic manufacturers could lead to shifts in pricing power.
- Increased Manufacturing Efficiency: Innovations in manufacturing processes could lead to modest price reductions.
- Competition and Volume: The market is highly price-sensitive, and competition among generic players will continue to exert downward pressure, albeit at a slower pace than during the initial generic entry.
- Payer Negotiations: Continued strong negotiation power from payers will ensure that net prices remain suppressed. Payers will likely continue to favor generics, pushing for further cost reductions.
Factors Influencing Future Pricing
- Generic Manufacturer Landscape: The number and competitive intensity of generic esomeprazole manufacturers will be a primary determinant of pricing.
- Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients can impact manufacturing costs and, subsequently, pricing.
- Regulatory Environment: Changes in FDA regulations or import policies could affect the supply and cost of generic drugs.
- Emergence of New Therapies: While unlikely to significantly impact established PPIs in the short term, the development of novel treatments for acid-related disorders could eventually influence demand for esomeprazole.
- Healthcare Reform: Broader changes in healthcare policy in the U.S. could alter reimbursement structures and drug pricing regulations.
What is the Outlook for Nexium (NDC 60505-4631)?
The outlook for Nexium (esomeprazole magnesium, NDC 60505-4631) is that of a mature, genericized drug with stable, low pricing.
Market Position
- Branded Nexium: Market presence will continue to decline and become virtually non-existent outside of specific, limited patient populations or payer situations. Its role will be minimal.
- Generic Esomeprazole Magnesium: Will remain a standard of care for its approved indications. It will compete within a crowded generic PPI market, with pricing driven by cost-efficiency and market share battles among manufacturers.
Key Considerations for Stakeholders
- Generic Manufacturers: Focus on maintaining cost-effective production, ensuring consistent supply, and securing favorable contracts with PBMs and distributors. Monitoring raw material costs and regulatory changes is crucial.
- Payers: Continue to leverage formulary placement and negotiation power to secure the lowest possible prices for generic esomeprazole magnesium.
- Healthcare Providers: Prescribing decisions will overwhelmingly favor the most cost-effective generic options, prioritizing patient access and affordability.
- Investors: Investment in branded Nexium will yield minimal returns. Opportunities lie in the generic manufacturing space, focusing on efficient production and market penetration strategies.
Key Takeaways
- Nexium (esomeprazole magnesium, NDC 60505-4631) is a mature drug market dominated by generic competition.
- Branded Nexium pricing has significantly eroded and will continue to do so, with a minimal market share.
- Generic esomeprazole magnesium pricing is expected to stabilize within a range of $8 to $25 per 30-count bottle, with modest potential for further decline.
- Pricing is primarily driven by generic competition, payer negotiations, and manufacturing costs.
- The future market will be characterized by continued generic availability and competitive pricing.
Frequently Asked Questions
1. How does the price of branded Nexium compare to generic esomeprazole magnesium?
Branded Nexium, prior to widespread generic entry, commanded prices several hundred percent higher than current generic esomeprazole magnesium prices. For example, a 30-count bottle of branded Nexium might have been priced between $250-$350, while generic equivalents now range from $8-$25 for the same quantity and dosage.
2. What is the primary reason for the drastic price reduction of Nexium?
The primary reason for the drastic price reduction is the expiration of key patents, allowing multiple pharmaceutical companies to manufacture and sell generic versions of esomeprazole magnesium. This increased competition significantly drives down prices.
3. Will branded Nexium be discontinued due to generic availability?
While branded Nexium's market share has drastically reduced, it is unlikely to be immediately discontinued. It may persist for niche markets, patients with specific insurance coverage, or through limited distribution agreements. However, its commercial relevance will be minimal.
4. What factors could lead to a significant price increase for generic esomeprazole magnesium?
Significant price increases for generic esomeprazole magnesium are unlikely in the current competitive landscape. Potential drivers for a price surge would include widespread supply chain disruptions affecting API availability, major manufacturing plant failures across multiple key suppliers, or a drastic shift in regulatory requirements that increases production costs substantially.
5. How do payer formularies influence the price of generic esomeprazole magnesium?
Payer formularies exert substantial downward pressure on generic esomeprazole magnesium prices. Payers, including pharmacy benefit managers (PBMs) and insurance companies, negotiate aggressively with generic manufacturers to secure preferred formulary placement. This negotiation power ensures that net prices for generics remain low, as payers often mandate the lowest available cost-effective option.
Citations
[1] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Common digestive diseases. U.S. Department of Health and Human Services. Retrieved from https://www.niddk.nih.gov/health-information/digestive-diseases/common-digestive-diseases
[2] AstraZeneca. (2023). Annual Report 2022. Retrieved from https://www.astrazeneca.com/content/dam/az/Investors/Reporting%20centre/Annual%20reports%20and%20results/2022/annual-report-2022.pdf (Note: Specific sales figures for branded Nexium vs. generics may require access to detailed segment reports not publicly available in the main annual report).
[3] U.S. Food & Drug Administration. (2015). FDA approves first generic version of Nexium capsules. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-generic-version-nexium-capsules (This reference confirms generic approval, implying subsequent price shifts).
More… ↓
